Drug ID:Drug154
Drug Name:GSK2982772
CID:77108121
DrugBank ID:DB16875
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT02903966
Molecular Formula:C20H19N5O3
Molecular Weight:377.4 g/mol
Isomeric SMILES:CN1C2=CC=CC=C2OC[C@@H](C1=O)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4
Synonyms:GSK2982772; 1622848-92-3; (S)-3-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-5-carboxamide; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; T5W3M0VO9B; CHEMBL4071864; 1622848-92-3 (free base); 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydro-1,5-Benzoxazepin-3-Yl]-1h-1,2,4-Triazole-5-Carboxamide
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1198 77108121 (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide 8737 RIPK1 Homo sapiens (human) 28151659 Inhibition
dt1199 77108121 (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide 8737 RIPK1 Homo sapiens (human) 34389633 Receptor-interacting serine/threonine-protein kinase 1 inhibitor
dt1200 77108121 (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide 8737 RIPK1 Homo sapiens (human) Inhibitor
dt1201 77108121 (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide 8737 RIPK1 Homo sapiens (human) 28151659 Inhibitor

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT02903966 GSK2982772 Study in Subjects With Ulcerative Colitis PHASE2 COMPLETED GlaxoSmithKline Colitis, Ulcerative DRUG: GSK2982772|DRUG: Placebo Details
NCT02302404 A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects PHASE1 COMPLETED GlaxoSmithKline Inflammatory Bowel Diseases DRUG: GSK2982772 solution|DRUG: GSK2982772 capsul… Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05666960 R-3750 in Patients With Mild to Moderate Ulcerative Colitis PHASE1 RECRUITING Rise Therapeutics LLC Ulcerative Colitis Chronic Mild|Ulcerative Coliti… DRUG: R-3750 Details
NCT05659953 LMT503 First-in-human SAD, MAD, and FE Study PHASE1 NOT_YET_RECRUITING Lmito Therapeutics Inc. Inflammatory Bowel Disease|Colitis, Ulcerative|Cr… DRUG: LMT503|DRUG: Placebo Details
NCT05624801 Cholecalciferol Comedication in Patients With Chronic Inflammatory Bowel Diseases (Crohn's Disease or Ulcerative Colitis) - the 5C-study PHASE3 Recruiting University Hospital, Basel, Switzerland IBD Drug: D3 VitaCaps Details
NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Sanofi Colitis Ulcerative DRUG: SAR443122|DRUG: Placebo Details
NCT05528510 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis PHASE3 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… Details
NCT07161297 Remimazolam for Colonoscopy in IBD Patients PHASE4 NOT_YET_RECRUITING Humanitas Clinical and Research Center IBD (Inflammatory Bowel Disease) DRUG: Intravenous remimazolam (5 mg initially, wi… Details
NCT05509777 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease PHASE3 RECRUITING Eli Lilly and Company Crohn's Disease DRUG: Mirikizumab Details
NCT05507931 Broccoli Sprouts for Mild Ulcerative Colitis NA COMPLETED University of Michigan Ulcerative Colitis|Ulcerative Colitis Chronic Mild DIETARY_SUPPLEMENT: 1 Serving of broccoli sprouts… Details
NCT05377580 A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis PHASE2 COMPLETED Innovent Biologics (Suzhou) Co. Ltd. Ulcerative Colitis (UC) DRUG: Period 1 IBI112 Placebo|DRUG: Period 2 IBI1… Details
NCT07149441 Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study NA ACTIVE_NOT_RECRUITING Shanghai 10th People's Hospital Inflammatory Bowel Disease (Crohn&Amp;#39;s Disea… PROCEDURE: Fecal microbiota transplantation|DRUG:… Details
NCT05271838 Protein and Magnesium in Ulcerative Colitis NA UNKNOWN University of Aarhus Inflammatory Bowel Diseases|Colitis, Ulcerative|M… DIETARY_SUPPLEMENT: Magnesium acetate mixture (30… Details
NCT07132333 Molecular Inflammation Board at the Center for Personalized Medicine NULL RECRUITING University Hospital Tuebingen Psoriasis (PsO)|Psoriasis Arthritis|Inflammatory … BIOLOGICAL: Biologic Agent Details
NCT05242484 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… Details
NCT05242471 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease PHASE2 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Crohn's Disease BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… Details
NCT07123350 Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease NULL ACTIVE_NOT_RECRUITING Vanderbilt University Medical Center Inflammatory Bowel Disease (IBD)|Crohn&Amp;#39;s … DRUG: Patient switched from IV vedolizumab to sub… Details
NCT07123259 Ulcer Pomegranate Muffins NA COMPLETED University of Lahore Gastric|Peptic Ulcer DIETARY_SUPPLEMENT: WHOLE WHEAT MUFFIN|COMBINATIO… Details
NCT05197049 A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease PHASE3 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Crohn Disease DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patient…

PMID: 34389633
Year: 2021
Relationship Type: Treatment Score: 7.5

OBJECTIVE: Tumour necrosis factor signalling via the receptor-interacting protein kinase 1 (RIPK1) pathway regulates colonic inflammation suggesting …

View Details
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Spec…

PMID: 28151659
Year: 2017
Relationship Type: Treatment Score: 6.3

RIP1 regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediat…

View Details